t cells Search Results


95
ATCC primary cd4 t cells
Primary Cd4 T Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Primary+CD4%2B+Helper+T+Cells/pm38669943-143-10-19
Average 95 stars, based on 1 article reviews
primary cd4 t cells - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
MedChemExpress immunomagnetic separation kit
Immunomagnetic Separation Kit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13458028-145-14-25
Average 94 stars, based on 1 article reviews
immunomagnetic separation kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

99
Sartorius AG incucyte zoom
Incucyte Zoom, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Live+Cell+Analysis+Instruments/pm41963733-271-9-11
Average 99 stars, based on 1 article reviews
incucyte zoom - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

94
Boster Bio rabbit anti cd86
Rabbit Anti Cd86, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Anti-CD86+(Dendritic+Cells+Maturation+Marker)+Monoclonal+Antibody/pmc12858484-58-4-6
Average 94 stars, based on 1 article reviews
rabbit anti cd86 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
ATCC cd8 t cells
Cd8 T Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Primary+CD8%2B+Cytotoxic+T+Cells/pm10779756-53-24-32
Average 96 stars, based on 1 article reviews
cd8 t cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
ATCC primary bladder epithelial
Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder <t>epithelial</t> cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.
Primary Bladder Epithelial, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Primary+Bladder+Epithelial+(A%2FT%2FN)Cells%3B+Normal%2C+Human/pm39727167-53-40-60
Average 93 stars, based on 1 article reviews
primary bladder epithelial - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Cedarlane negative selection t cell purification columns
Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder <t>epithelial</t> cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.
Negative Selection T Cell Purification Columns, supplied by Cedarlane, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Mouse+T+Cell+Immunocolumns+(non-magnetic+purification+of+Mouse+T+cells)+Kit/pmc05794172-178-15-21
Average 93 stars, based on 1 article reviews
negative selection t cell purification columns - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
Cedarlane goat anti β2gpi
Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder <t>epithelial</t> cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.
Goat Anti β2gpi, supplied by Cedarlane, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Anti-Mouse+T+Cells+(Thy+1)+Lyophilized+(Polyclonal)+(rabbit+serum)/pmc05523967-173-0-3
Average 91 stars, based on 1 article reviews
goat anti β2gpi - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

86
ProSci Incorporated anti nfatc1 ab
Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder <t>epithelial</t> cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.
Anti Nfatc1 Ab, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/NFATC1+Antibody/pmc05481796-45-10-16
Average 86 stars, based on 1 article reviews
anti nfatc1 ab - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Cedarlane human t cell recovery immunocolumn kit
Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder <t>epithelial</t> cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.
Human T Cell Recovery Immunocolumn Kit, supplied by Cedarlane, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Human+T+Cell+Immunocolumns+(non-magnetic+purification+of+Human+T+cells)+Kit+(high+capacity)/pmc03135516-85-13-19
Average 93 stars, based on 1 article reviews
human t cell recovery immunocolumn kit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
iQ Biosciences human itregs
( A ) Experimental outline for in <t>vitro</t> <t>Treg</t> global transcriptomic analysis: total CD4 + T cell population isolated from FOXP3 reporter mice, followed by differentiating the isolated naive CD4 + T cells into induced Tregs <t>(iTregs).</t> The iTregs were exposed either to vehicle or human CDC-EVs for 5 days and subsequently assessed for transcriptomic changes. ( B and C ) Functional heatmap depicting enrichment in cell survival ( B ) and cellular movement ( C ) categories in the upregulated transcripts in CDC-EVs versus vehicle based on IPA analysis. ( D – F ) Human iTregs were exposed either to CDC-EVs or fibroblast EVs (NHDF-EVs) at indicated concentrations (0–5,000 EVs/cell) for 24 hours ( D ), 72 hours ( E ), and 5 days ( F ). ( G ) The migration of human iTregs following exposure to CDC-EVs or NHDF-EVs, toward 500 ng/mL recombinant CCL20, was assessed using a 24-well Transwell plate. ( H ) Real-time PCR analysis of IL-10 mRNA expression in human iTregs exposed to either CDC-EVs or NHDF-EVs for 72 hours. ( I ) Protein levels of IL-10 were assayed by ELISA in supernatants of human iTregs exposed to either CDC-EVs or NHDF-EVs for 72 hours. One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group.
Human Itregs, supplied by iQ Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Human+Induced+T+Regulatory+Cells/pmc12043100-208-0-5
Average 94 stars, based on 1 article reviews
human itregs - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
BPS Bioscience anti cd19 car t cells egfp
a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the <t>anti-CD19</t> mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.
Anti Cd19 Car T Cells Egfp, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cells/Anti-CD19+CAR-T+Cells/bio_rxiv__64898__2026__10__24__761515-182-6-14
Average 94 stars, based on 1 article reviews
anti cd19 car t cells egfp - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder epithelial cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.

Journal: Nucleic acids research

Article Title: Sequestration of ribosomal subunits as inactive 80S by targeting eIF6 limits mitotic exit and cancer progression.

doi: 10.1093/nar/gkae1272

Figure Lengend Snippet: Figure 9. Ov ere xpression of eIF6 observ ed primarily in high-grade in v asiv e bladder and breast cancers. ( A and B ) Western blot probed for eIF6 in human bladder cancer cell lines and healthy (normal) bladder epithelial cells. β-Tubulin used as loading control. Blots shown in panel (A) were quantitated and eIF6 le v els w ere normaliz ed to loading control and plotted (panel B) as FC o v er eIF6 le v els in normal bladder epithelial cells. Values indicate standard error of the mean from four independent experiments and significant differences for T24 ( P = 0.0065), UMUC3 ( P = 0.0132) and HT1197 ( P = 0.0017) determined by an unpaired t wo-t ailed t -test. ( C ) Images represent eIF6 expression in patient-derived benign and high-grade tumors by immunohistochemistry using anti-eIF6 antibody. Enlarged inset shows the presence of eIF6 in nucleoli and cytoplasm in high-grade cancers. ( D ) Images shown in panel (C) were quantitated and eIF6 expression in patient-matched benign tissues relative to high-grade cancers (six patients) were plotted. Significant differences were determined using an unpaired t wo-t ailed t -test ( P = 0.0063). ( E ) Plot shows eIF6 expression in unmatched benign tissues, high-grade and low-grade bladder cancers derived from patients. ( F and G ) Western blot represents high levels of eIF6 in high-grade invasive human triple negative breast cancer cell line. β-Tubulin used as loading control. Blots shown in panel (F) were quantitated and eIF6 levels were normalized to loading control and plotted (G) as FC o v er eIF6 le v els in normal (healthy) HME-1 cells. Values indicate standard error of the mean from four independent experiments and significant differences for MDA-MB-231 ( P = 0.001) determined by an unpaired t wo-t ailed t -test.

Article Snippet: The human bladder cancer cell lines HT1376, HT1197, UM-UC-3 and TCCSUP were maintained in EMEM media with 10% FBS and Penn / Strep, T-24 cell lines were maintained in McCoy’s 5A medium with 10% FBS and Penn / Strep and primary bladder epithelial (A / T / N): normal human (BdEC) cells were maintained in bladder epithelial cell basal medium (ATCC) supplemented with bladder epithelial g c i g b D W C [ a p 1 fl d t ( m a p c w m ( b l o β S 0 p B S C C e d s i S B m B s a ( S B a p a m t w s i i H 7 w f v D ow nloaded from https://academ ic.oup.com /nar/advance-article/doi/10.1093/nar/gkae1272/7933602 by guest on 30 D ecem ber 2024 rowth factors.

Techniques: Western Blot, Control, Expressing, Derivative Assay, Immunohistochemistry

( A ) Experimental outline for in vitro Treg global transcriptomic analysis: total CD4 + T cell population isolated from FOXP3 reporter mice, followed by differentiating the isolated naive CD4 + T cells into induced Tregs (iTregs). The iTregs were exposed either to vehicle or human CDC-EVs for 5 days and subsequently assessed for transcriptomic changes. ( B and C ) Functional heatmap depicting enrichment in cell survival ( B ) and cellular movement ( C ) categories in the upregulated transcripts in CDC-EVs versus vehicle based on IPA analysis. ( D – F ) Human iTregs were exposed either to CDC-EVs or fibroblast EVs (NHDF-EVs) at indicated concentrations (0–5,000 EVs/cell) for 24 hours ( D ), 72 hours ( E ), and 5 days ( F ). ( G ) The migration of human iTregs following exposure to CDC-EVs or NHDF-EVs, toward 500 ng/mL recombinant CCL20, was assessed using a 24-well Transwell plate. ( H ) Real-time PCR analysis of IL-10 mRNA expression in human iTregs exposed to either CDC-EVs or NHDF-EVs for 72 hours. ( I ) Protein levels of IL-10 were assayed by ELISA in supernatants of human iTregs exposed to either CDC-EVs or NHDF-EVs for 72 hours. One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group.

Journal: The Journal of Clinical Investigation

Article Title: Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

doi: 10.1172/JCI179262

Figure Lengend Snippet: ( A ) Experimental outline for in vitro Treg global transcriptomic analysis: total CD4 + T cell population isolated from FOXP3 reporter mice, followed by differentiating the isolated naive CD4 + T cells into induced Tregs (iTregs). The iTregs were exposed either to vehicle or human CDC-EVs for 5 days and subsequently assessed for transcriptomic changes. ( B and C ) Functional heatmap depicting enrichment in cell survival ( B ) and cellular movement ( C ) categories in the upregulated transcripts in CDC-EVs versus vehicle based on IPA analysis. ( D – F ) Human iTregs were exposed either to CDC-EVs or fibroblast EVs (NHDF-EVs) at indicated concentrations (0–5,000 EVs/cell) for 24 hours ( D ), 72 hours ( E ), and 5 days ( F ). ( G ) The migration of human iTregs following exposure to CDC-EVs or NHDF-EVs, toward 500 ng/mL recombinant CCL20, was assessed using a 24-well Transwell plate. ( H ) Real-time PCR analysis of IL-10 mRNA expression in human iTregs exposed to either CDC-EVs or NHDF-EVs for 72 hours. ( I ) Protein levels of IL-10 were assayed by ELISA in supernatants of human iTregs exposed to either CDC-EVs or NHDF-EVs for 72 hours. One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group.

Article Snippet: Human iTregs were purchased from IQ Biosciences (IQB-Hu1-iTr-1) and expanded (Treg Expansion Kit, Miltenyi Biotec, 130-095-353) according to the manufacturer’s protocol.

Techniques: In Vitro, Isolation, Functional Assay, Migration, Recombinant, Real-time Polymerase Chain Reaction, Expressing, Enzyme-linked Immunosorbent Assay, Control

( A ) RNA-Seq of CDC-EVs shows lncRNA to be plentiful compared with NHDF-EVs. ( B ) List of top 10 most plentiful lncRNAs, among which BCYRN1 is the highest enriched in CDC-EVs (CDC-EVs [blue bars] and NHDF-EVs [orange bars]). ( C ) BCYRN1 is expressed more in CDC-EVs than in NHDF-EVs by qPCR. ( D ) Confocal microscopy shows uptake of PKH26-labeled CDC-EVs by human iTregs. Scale bar: 5 μm. ( E ) Assessment of BCYRN1 expression by qPCR in human iTregs exposed to CDC-EVs or NHDF-EVs for indicated times. One-way ANOVA followed by Bonferroni’s post hoc test was used to assess statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control (Ctrl) group.

Journal: The Journal of Clinical Investigation

Article Title: Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

doi: 10.1172/JCI179262

Figure Lengend Snippet: ( A ) RNA-Seq of CDC-EVs shows lncRNA to be plentiful compared with NHDF-EVs. ( B ) List of top 10 most plentiful lncRNAs, among which BCYRN1 is the highest enriched in CDC-EVs (CDC-EVs [blue bars] and NHDF-EVs [orange bars]). ( C ) BCYRN1 is expressed more in CDC-EVs than in NHDF-EVs by qPCR. ( D ) Confocal microscopy shows uptake of PKH26-labeled CDC-EVs by human iTregs. Scale bar: 5 μm. ( E ) Assessment of BCYRN1 expression by qPCR in human iTregs exposed to CDC-EVs or NHDF-EVs for indicated times. One-way ANOVA followed by Bonferroni’s post hoc test was used to assess statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control (Ctrl) group.

Article Snippet: Human iTregs were purchased from IQ Biosciences (IQB-Hu1-iTr-1) and expanded (Treg Expansion Kit, Miltenyi Biotec, 130-095-353) according to the manufacturer’s protocol.

Techniques: RNA Sequencing, Confocal Microscopy, Labeling, Expressing, Control

( A – C ) Effects of overexpression (OE) of BCYRN1 in human iTregs on proliferation ( A ), migration ( B ), and IL-10 production ( C ). ( D and E ) Transfection of CDCs with siRNA-BCYRN1 results in knockdown of BCYRN1 in both CDCs and CDC-EVs. ( F – H ) Exposure of human iTregs to CDC-EVs with BCYRN1 knockdown followed by assessments of proliferation ( F ), migration ( G ), and IL-10 production ( H ). One-way ANOVA followed by Bonferroni’s post hoc test was used to assess statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group. ## P < 0.01 versus si-Ctrl-CDC-EVs group.

Journal: The Journal of Clinical Investigation

Article Title: Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

doi: 10.1172/JCI179262

Figure Lengend Snippet: ( A – C ) Effects of overexpression (OE) of BCYRN1 in human iTregs on proliferation ( A ), migration ( B ), and IL-10 production ( C ). ( D and E ) Transfection of CDCs with siRNA-BCYRN1 results in knockdown of BCYRN1 in both CDCs and CDC-EVs. ( F – H ) Exposure of human iTregs to CDC-EVs with BCYRN1 knockdown followed by assessments of proliferation ( F ), migration ( G ), and IL-10 production ( H ). One-way ANOVA followed by Bonferroni’s post hoc test was used to assess statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group. ## P < 0.01 versus si-Ctrl-CDC-EVs group.

Article Snippet: Human iTregs were purchased from IQ Biosciences (IQB-Hu1-iTr-1) and expanded (Treg Expansion Kit, Miltenyi Biotec, 130-095-353) according to the manufacturer’s protocol.

Techniques: Over Expression, Migration, Transfection, Knockdown, Control

( A ) Human iTregs were exposed to CDC-EVs or not treated (ctrl). The expression of autophagy markers (MAP1LC3B, ATG7, and SQSTM1) was assessed by Western blot (WB). ( B ) Human iTregs were exposed to ctrl-CDC-EVs or si-BCYRN1 CDC-EVs (EV with BCYRN1 knockdown), or were not treated (ctrl). Expression of autophagy markers (MAP1LC3B, ATG7, and SQSTM1) was assessed by WB. ( C ) Human iTregs were transfected with vector or OE-BCYRN1 lenti-vector, followed by assessment of autophagy markers by WB. ( D ) Biotin-labeled BCYRN1 probe was used to pull down BCYRN1-associated RNAs, followed by assessment of miR-138, negative control ( U6 and GAPDH ), and positive control (BCYRN1) expression by qPCR. ( E ) The top panel shows putative lncRNA BCYRN1 binding sites in miR-138. The bottom panel shows human iTregs that were cotransfected with WT or mutant luciferase reporters with mimic miR-138 into HEK-293T cells, followed by assessment of relative luciferase activity. ( F ) Cotransfection of miR-138 and BCYRN1 in Tregs followed by assessments of ATG7 by WB. One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group.

Journal: The Journal of Clinical Investigation

Article Title: Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

doi: 10.1172/JCI179262

Figure Lengend Snippet: ( A ) Human iTregs were exposed to CDC-EVs or not treated (ctrl). The expression of autophagy markers (MAP1LC3B, ATG7, and SQSTM1) was assessed by Western blot (WB). ( B ) Human iTregs were exposed to ctrl-CDC-EVs or si-BCYRN1 CDC-EVs (EV with BCYRN1 knockdown), or were not treated (ctrl). Expression of autophagy markers (MAP1LC3B, ATG7, and SQSTM1) was assessed by WB. ( C ) Human iTregs were transfected with vector or OE-BCYRN1 lenti-vector, followed by assessment of autophagy markers by WB. ( D ) Biotin-labeled BCYRN1 probe was used to pull down BCYRN1-associated RNAs, followed by assessment of miR-138, negative control ( U6 and GAPDH ), and positive control (BCYRN1) expression by qPCR. ( E ) The top panel shows putative lncRNA BCYRN1 binding sites in miR-138. The bottom panel shows human iTregs that were cotransfected with WT or mutant luciferase reporters with mimic miR-138 into HEK-293T cells, followed by assessment of relative luciferase activity. ( F ) Cotransfection of miR-138 and BCYRN1 in Tregs followed by assessments of ATG7 by WB. One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4 individual experiments (biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group.

Article Snippet: Human iTregs were purchased from IQ Biosciences (IQB-Hu1-iTr-1) and expanded (Treg Expansion Kit, Miltenyi Biotec, 130-095-353) according to the manufacturer’s protocol.

Techniques: Expressing, Western Blot, Knockdown, Transfection, Plasmid Preparation, Labeling, Negative Control, Positive Control, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Cotransfection, Control

( A ) Human iTregs were exposed to CDC-EVs or were not treated (ctrl). The expression of CCR6 was assessed by qPCR. ( B ) Human Tregs were exposed to ctrl-CDC-EVs or si-BCYRN1 CDC-EVs (EV with BCYRN1 knockdown) or were not treated (ctrl). The expression of CCR6 was assessed by qPCR. ( C ) Human Tregs were transfected with vector or OE-BCYRN1 lenti-vector, followed by assessment of CCR6 by qPCR. ( D ) Biotin-labeled BCYRN1 probe was used to pull down BCYRN1-associated RNAs, followed by assessment of miR-150, negative control (U6 and GAPDH), and positive control (BCYRN1) expression by qPCR. ( E ) The top panels putative lncRNA BCYRN1 binding sites in miR-150. The bottom panel shows human iTregs that were cotransfected with WT or mutant luciferase reporters and mimic miR-150 into HEK-293T cells, followed by the assessment of relative luciferase activity. ( F and G ). Cotransfection of miR-150 and BCYRN1 in Tregs followed by assessments of CCR6 by WB ( F ) and cellular migration by trans-well migration assay ( G ). One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4individual experiments (biological replicates). ** P < 0.01, *** P < 0.001 versus control group. ### P < 0.001 versus miR-150 group.

Journal: The Journal of Clinical Investigation

Article Title: Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

doi: 10.1172/JCI179262

Figure Lengend Snippet: ( A ) Human iTregs were exposed to CDC-EVs or were not treated (ctrl). The expression of CCR6 was assessed by qPCR. ( B ) Human Tregs were exposed to ctrl-CDC-EVs or si-BCYRN1 CDC-EVs (EV with BCYRN1 knockdown) or were not treated (ctrl). The expression of CCR6 was assessed by qPCR. ( C ) Human Tregs were transfected with vector or OE-BCYRN1 lenti-vector, followed by assessment of CCR6 by qPCR. ( D ) Biotin-labeled BCYRN1 probe was used to pull down BCYRN1-associated RNAs, followed by assessment of miR-150, negative control (U6 and GAPDH), and positive control (BCYRN1) expression by qPCR. ( E ) The top panels putative lncRNA BCYRN1 binding sites in miR-150. The bottom panel shows human iTregs that were cotransfected with WT or mutant luciferase reporters and mimic miR-150 into HEK-293T cells, followed by the assessment of relative luciferase activity. ( F and G ). Cotransfection of miR-150 and BCYRN1 in Tregs followed by assessments of CCR6 by WB ( F ) and cellular migration by trans-well migration assay ( G ). One-way ANOVA followed by Bonferroni’s post hoc test was used to determine statistical significance. All data are presented as mean ± SEM of 3 or 4individual experiments (biological replicates). ** P < 0.01, *** P < 0.001 versus control group. ### P < 0.001 versus miR-150 group.

Article Snippet: Human iTregs were purchased from IQ Biosciences (IQB-Hu1-iTr-1) and expanded (Treg Expansion Kit, Miltenyi Biotec, 130-095-353) according to the manufacturer’s protocol.

Techniques: Expressing, Knockdown, Transfection, Plasmid Preparation, Labeling, Negative Control, Positive Control, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Cotransfection, Migration, Control

a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.

Journal: bioRxiv

Article Title: CD19-CAR T-cell therapy resets the EBV + autoreactive B cell repertoire in autoimmune disease

doi: 10.64898/2026.10.24.761515

Figure Lengend Snippet: a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.

Article Snippet: For CD19 CAR T cell–mediated cytotoxicity, anti-CD19 CAR T cells (eGFP) were obtained from BPS Bioscience (Cat#78789) and co-cultured with target cells at E:T ratios of 1:1, 2:1, and 5:1 for 24 hours.

Techniques: Quantitative Proteomics, Labeling, Sequencing, In Vitro, Analysis, Bioprocessing